Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyMolina Pombiliti Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentMolina HealthcarePolicy C27242-A

    Pombiliti (cipaglucosidase alfa-atga) Coverage for Late-Onset Pompe Disease

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C27242-A alerts

    Get alerted when Policy C27242-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for intravenous Pombiliti used with Opfolda to treat adults with late-onset Pompe disease who weigh at least 40 kg and are not improving on current enzyme replacement therapy.

    Policy Summary
    PayerMolina Healthcare
    PolicyPombiliti (cipaglucosidase alfa-atga) Coverage for Late-Onset Pompe Disease
    Policy CodePolicy C27242-A
    Change TypeNo material clinical or coverage change
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit documentation of the diagnosis, confirmatory testing, weight of at least 40 kg, baseline clinical measures, and lack of improvement on current enzyme replacement therapy for prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥40 kgMinimum member weight
    18+Minimum age
    20 mg/kgDose
    Every other weekAdministration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 monthsAuthorization duration
    PregnancyContraindication

    Coverage Criteria

    Initial Therapy Criteria

    Covered when ALL of the following initial therapy criteria are met:

    Initial therapy

    • Diagnosis

      • The member has a documented diagnosis of late-onset Pompe disease (LOPD).
      • ONE of the following diagnostic confirmations

        • An enzyme assay shows deficiency of acid alpha-glucosidase (GAA) activity in blood, skin, or muscle.

          Documentation required.

        • Genetic testing shows a mutation in the GAA gene.

          Documentation required.

    • Clinical eligibility

      • The member weighs at least 40 kg.≥40 kg
      • Baseline percent-predicted forced vital capacity (FVC), baseline walking distance or 6-minute walk test (6MWT), or gastrointestinal symptoms are documented.

        Documentation required.

      • The member is not improving on current enzyme replacement therapy (ERT) and is not ERT-naive.

        Documentation required.

    • Combination and safety requirements

      • Pombiliti will not be used concurrently with Nexviazyme (avalglucosidase alfa-ngpt) or Lumizyme (alglucosidase alfa).
      • Opfolda (miglustat) has been authorized for concurrent use.
      • The prescriber attests, or the clinical reviewer confirms, that the member has no unaddressed FDA-labeled contraindication to Pombiliti.

        Pregnancy is a listed contraindication.

    Continuation Therapy Criteria

    Covered for continuation when ALL of the following criteria are met:

    Continuation therapy

    • The prescriber attests, or the clinical reviewer confirms, that there is no evidence of intolerable adverse effects or drug toxicity, including severe infusion-related reactions.
    • Documentation shows a beneficial response to therapy compared with the pretreatment baseline, demonstrated by stabilization or improvement in FVC and/or 6MWT and signs or symptoms of the condition, such as gastrointestinal symptoms.

      Documentation required.

    • The member is able to take Opfolda 1 to 3 hours before each Pombiliti infusion.1–3 hours before each infusion

    FDA-Approved Indication

    Pombiliti is covered for the following FDA-approved use:

    FDA-approved indication

    • The patient is an adult with late-onset Pompe disease caused by lysosomal acid alpha-glucosidase (GAA) deficiency.
    • The patient weighs at least 40 kg.≥40 kg
    • The patient is not improving on current enzyme replacement therapy (ERT).
    • Pombiliti is administered in combination with Opfolda, an enzyme stabilizer.

    Pombiliti must not be used concurrently with Nexviazyme (avalglucosidase alfa-ngpt) or Lumizyme (alglucosidase alfa).

    Coverage requires concurrent authorization of Opfolda (miglustat) for use with Pombiliti. If the Pombiliti infusion cannot begin within 3 hours after oral Opfolda, the combination must be rescheduled for at least 24 hours after Opfolda was last taken.

    All other uses of Pombiliti with Opfolda are considered experimental/investigational and follow Molina's Off-Label policy.

    Pregnancy is a contraindication to Pombiliti. Any contraindication not addressed by the prescriber in the submitted documentation may affect coverage.

    Coding and Billing Information

    Coding/Billing InformationHCPCS
    J1203Injection, cipaglucosidase alfa-atga, 5 mg
    Minimum Body Weight
    Minimum body weightAt least 40 kg
    Coverage relevanceRequired for Pombiliti use in adult patients with late-onset Pompe disease
    DocumentationSubmit the member's current weight for review
    Baseline Respiratory Assessment
    Required measurePercent-predicted forced vital capacity (FVC)
    TimingDocument the member's baseline value before treatment
    Clinical use

    Authorization and Provider Requirements

    Prior Authorization

    Initial Clinical Authorization

    Submit an initial clinical authorization request documenting Pompe disease, confirmatory GAA testing, member weight, and the supporting clinical records needed to establish medical necessity. Weight, body surface area, or other member-specific dosing data is required when applicable.

    • Provide diagnosis and confirmatory testing documentation.
    • Document member weight of at least 40 kg and any required dosing measurements.
    • Include baseline disease measures, current ERT status and response, and other supporting records.
    Denial Risk

    Clinical Eligibility Failures

    Coverage may be denied when clinical eligibility requirements are not met, including inadequate weight, lack of required baseline disease documentation, improvement on current ERT, concurrent use of another ERT, or failure to satisfy the required combination-therapy and contraindication criteria.

    Clinical Background

    Pombiliti (cipaglucosidase alfa-atga) is a hydrolytic lysosomal glycogen-specific enzyme used with the oral enzyme stabilizer Opfolda (miglustat). Coverage addresses adults with late-onset Pompe disease who weigh at least 40 kg and are not improving on current enzyme replacement therapy.

    Definitions

    Late-Onset Pompe Disease
    AbbreviationLOPD
    Underlying deficiencyLysosomal acid alpha-glucosidase (GAA) deficiency
    Diagnostic confirmationConfirmed by an enzyme assay showing GAA deficiency or genetic testing showing a GAA gene mutation
    Percent-Predicted FVC
    MeaningForced vital capacity expressed as a percentage of the predicted value for the member
    Baseline roleUsed as a baseline respiratory assessment
    Continuation roleStabilization or improvement in FVC may demonstrate beneficial response to therapy

    Initial Therapy

    Initial Therapy Criteria

    Initial therapy requires ALL of the following:

    Initial Pombiliti therapy

    • The member has a documented diagnosis of late-onset Pompe disease confirmed by an enzyme assay showing deficiency of acid alpha-glucosidase (GAA) activity in blood, skin, or muscle, or by genetic testing showing a mutation in the GAA gene.

      Documentation required.

    • The member weighs at least 40 kg.≥40 kg
    • Baseline percent-predicted FVC, baseline walking distance or 6MWT, or gastrointestinal symptoms are documented.

      Documentation required.

    Continuation of Therapy

    Continuation of Therapy Criteria

    Continuation requires ALL of the following:

    Continuation of therapy

    • The prescriber attests, or the clinical reviewer confirms, that there is no evidence of intolerable adverse effects or drug toxicity, including severe infusion-related reactions.
    • Documentation shows a beneficial response to therapy compared with the pretreatment baseline, demonstrated by stabilization or improvement in FVC and/or 6MWT and signs or symptoms of the condition, such as gastrointestinal symptoms.

      Documentation required.

    • The member is able to take Opfolda 1 to 3 hours before each Pombiliti infusion.1–3 hours before each infusion

    Step Therapy Requirement

    StepRequired prior therapyFailure criterion
    1Member must not be enzyme replacement therapy (ERT)-naive.Documented lack of improvement on current ERT before Pombiliti authorization.

    Dosing and Quantity Limits

    Pombiliti Dosing
    Dose20 mg/kg
    Weight basisActual body weight
    FrequencyEvery other week

    Site-of-Care Requirements

    Note

    Use a non-hospital facility-based setting

    Infused Pombiliti is recommended for pharmacy or medical benefit coverage when administered in a non-hospital facility-based location under Molina’s Site of Care program.

    Policy Summary
    PayerMolina Healthcare
    PolicyPombiliti (cipaglucosidase alfa-atga) Coverage for Late-Onset Pompe Disease
    Policy CodePolicy C27242-A
    Change TypeNo material clinical or coverage change
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit documentation of the diagnosis, confirmatory testing, weight of at least 40 kg, baseline clinical measures, and lack of improvement on current enzyme replacement therapy for prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Billing InformationAuthorization and Provider RequirementsClinical BackgroundDefinitionsInitial TherapyContinuation of TherapyStep Therapy RequirementDosing and Quantity LimitsSite-of-Care Requirements
    FVC is used to assess baseline respiratory status and response to therapy
    Baseline Walking Assessment
    Required measureBaseline walking distance or 6-minute walk test (6MWT)
    TimingDocument the baseline assessment before treatment
    Clinical useWalking capacity is assessed for stabilization or improvement during therapy
    Patient Weight
    Minimum patient weightAt least 40 kg
    PopulationAdult patients with late-onset Pompe disease
    Treatment contextPombiliti must be used in combination with Opfolda
    • Member must weigh at least 40 kg.
    • Member must not be ERT-naïve and must be documented as not improving on current ERT.
    • Pombiliti must not be used concurrently with Nexviazyme or Lumizyme.
    • Required Opfolda authorization and contraindication attestations must be documented.
    Denial Risk

    Required Combination Therapy and Contraindications

    Pombiliti must be authorized for concurrent use with Opfolda and must not be used with Nexviazyme or Lumizyme. The prescriber must attest, or the clinical reviewer must confirm, that FDA-labeled contraindications have been addressed; pregnancy is a listed contraindication.

    • Document authorization for Opfolda (miglustat) for concurrent use.
    • If the infusion cannot begin within 3 hours after oral Opfolda, reschedule the combination at least 24 hours after Opfolda was last taken.
    • Address any FDA-labeled contraindications in the submitted documentation.
    Prior Authorization

    Qualified Prescriber

    Pombiliti must be prescribed by or in consultation with a qualified specialist experienced in Pompe disease management.

    • Acceptable prescribers or consultants include a metabolic specialist, endocrinologist, biochemical geneticist, or physician experienced in managing Pompe disease.

    Unsupported block type: documentation

    Unsupported block type: prior_auth

    Unsupported block type: info

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: prior_auth

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: billing_rule

    6-Minute Walk Test
    PurposeMeasures walking distance over six minutes
    Initial assessmentDocumented as a baseline measure before treatment
    Continuation assessmentUsed to evaluate stabilization or improvement during therapy
    Opfolda
    Generic nameMiglustat
    RoleOral enzyme stabilizer used concurrently with Pombiliti
    Coverage requirementOpfolda must be authorized for concurrent use with Pombiliti
    Pompe Disease
    Underlying disorderLysosomal acid alpha-glucosidase (GAA) deficiency
    Alternate nameAcid maltase deficiency
    Former classificationGlycogen storage disease type II (GSD II)
    Late-Onset Pompe Disease
    Disease formJuvenile or adult-onset form of GAA deficiency
    Primary clinical featureCharacterized by skeletal myopathy, usually in a limb-girdle distribution
    Disease courseProtracted course that may lead to respiratory failure
    Enzyme Replacement Therapy
    ERT meaningEnzyme replacement therapy intended to replace deficient lysosomal GAA activity
    Pombiliti relationshipPombiliti is an enzyme replacement therapy for Pompe disease
    Combination treatmentPombiliti is used with the enzyme stabilizer Opfolda
    The member is not improving on current ERT and is not ERT-naive.

    Documentation required.

  1. Pombiliti will not be used concurrently with Nexviazyme or Lumizyme.
  2. Opfolda has been authorized for concurrent use.
  3. The prescriber attests, or the clinical reviewer confirms, that the member has no unaddressed FDA-labeled contraindication to Pombiliti.

    Pregnancy is a listed contraindication.

  4. Initial Therapy: Pombiliti in Combination With Opfolda

    Pombiliti is indicated only in combination with Opfolda for the specified adult late-onset Pompe disease population.

    Approved combination use

    • The patient is an adult with late-onset Pompe disease due to lysosomal acid alpha-glucosidase (GAA) deficiency.
    • The patient weighs at least 40 kg.≥40 kg
    • The patient is not improving on current enzyme replacement therapy (ERT).
    • Pombiliti will be administered in combination with Opfolda (miglustat).